[go: up one dir, main page]

FR3041639B1 - NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT - Google Patents

NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT Download PDF

Info

Publication number
FR3041639B1
FR3041639B1 FR1559252A FR1559252A FR3041639B1 FR 3041639 B1 FR3041639 B1 FR 3041639B1 FR 1559252 A FR1559252 A FR 1559252A FR 1559252 A FR1559252 A FR 1559252A FR 3041639 B1 FR3041639 B1 FR 3041639B1
Authority
FR
France
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
pyridine derivatives
containing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1559252A
Other languages
English (en)
Other versions
FR3041639A1 (fr
Inventor
Balazs BALINT
Andras Kotschy
Melinda SIPOS
Csaba Weber
Nicolas Foloppe
David WALMSLEY
Frank Burbridge Michael
Francisco Humberto CRUZALEGUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Vernalis R&D Ltd
Original Assignee
Laboratoires Servier SAS
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1559252A priority Critical patent/FR3041639B1/fr
Application filed by Laboratoires Servier SAS, Vernalis R&D Ltd filed Critical Laboratoires Servier SAS
Priority to PE2018000443A priority patent/PE20181331A1/es
Priority to KR1020187012175A priority patent/KR20180054858A/ko
Priority to CA2999935A priority patent/CA2999935A1/fr
Priority to JP2018516194A priority patent/JP2018535931A/ja
Priority to MA043020A priority patent/MA43020A/fr
Priority to HK18114643.2A priority patent/HK1255804A1/zh
Priority to PCT/EP2016/073395 priority patent/WO2017055530A1/fr
Priority to CUP2018000028A priority patent/CU20180028A7/xx
Priority to AU2016333505A priority patent/AU2016333505A1/en
Priority to TNP/2018/000090A priority patent/TN2018000090A1/en
Priority to US15/763,248 priority patent/US20180273528A1/en
Priority to CN201680058054.0A priority patent/CN108137581A/zh
Priority to EA201890821A priority patent/EA201890821A1/ru
Priority to BR112018006157A priority patent/BR112018006157A2/pt
Priority to MX2018003860A priority patent/MX2018003860A/es
Priority to CR20180181A priority patent/CR20180181A/es
Priority to EP16774682.5A priority patent/EP3356363A1/fr
Publication of FR3041639A1 publication Critical patent/FR3041639A1/fr
Priority to SV2018005657A priority patent/SV2018005657A/es
Priority to NI201800043A priority patent/NI201800043A/es
Priority to PH12018500650A priority patent/PH12018500650A1/en
Priority to IL258341A priority patent/IL258341A/en
Priority to CL2018000783A priority patent/CL2018000783A1/es
Priority to ECIEPI201823253A priority patent/ECSP18023253A/es
Priority to DO2018000083A priority patent/DOP2018000083A/es
Priority to CONC2018/0003473A priority patent/CO2018003473A2/es
Application granted granted Critical
Publication of FR3041639B1 publication Critical patent/FR3041639B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne les composés de formule (I) : où R1, R2, R3, R4 et Rs sont tels que définis dans la description. L'invention concerne également des médicaments.
FR1559252A 2015-09-30 2015-09-30 NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT Expired - Fee Related FR3041639B1 (fr)

Priority Applications (26)

Application Number Priority Date Filing Date Title
FR1559252A FR3041639B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MX2018003860A MX2018003860A (es) 2015-09-30 2016-09-30 Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CA2999935A CA2999935A1 (fr) 2015-09-30 2016-09-30 Nouveaux derives d'imidazo[4,5-b]pyridine utilises comme inhibiteurs de dyrk1/clk1 doubles
JP2018516194A JP2018535931A (ja) 2015-09-30 2016-09-30 二重ＤＹＲＫ１／ＣＬＫ１阻害剤としての新規イミダゾ［４，５−ｂ］ピリジン誘導体
MA043020A MA43020A (fr) 2015-09-30 2016-09-30 Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles
HK18114643.2A HK1255804A1 (zh) 2015-09-30 2016-09-30 作为双重dyrk1/clk1抑制剂的新的咪唑并[4，5-b]吡啶衍生物
PCT/EP2016/073395 WO2017055530A1 (fr) 2015-09-30 2016-09-30 Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles
CUP2018000028A CU20180028A7 (es) 2015-09-30 2016-09-30 DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
AU2016333505A AU2016333505A1 (en) 2015-09-30 2016-09-30 New imidazo(4,5-B)pyridine derivatives as dual DYRK1/CLK1 inhibitors
TNP/2018/000090A TN2018000090A1 (en) 2015-09-30 2016-09-30 New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
US15/763,248 US20180273528A1 (en) 2015-09-30 2016-09-30 IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN201680058054.0A CN108137581A (zh) 2015-09-30 2016-09-30 作为双重DYRK1/CLK1抑制剂的新的咪唑并[4,5-b]吡啶衍生物
EA201890821A EA201890821A1 (ru) 2015-09-30 2016-09-30 НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
BR112018006157A BR112018006157A2 (pt) 2015-09-30 2016-09-30 derivados de imidazo[4,5-b]piridina como inibidores duplos de dyrk1/clk1
PE2018000443A PE20181331A1 (es) 2015-09-30 2016-09-30 NUEVOS DERIVADOS DE IMIDAZO [4,5-b] PIRIDINA UN PROCESO PARA SU PREPRACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
CR20180181A CR20180181A (es) 2015-09-30 2016-09-30 Nuevos derivados de imidazol[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
KR1020187012175A KR20180054858A (ko) 2015-09-30 2016-09-30 이중 dyrk1/clk1 억제제로서의 신규한 이미다조[4,5-b]피리딘 유도체
EP16774682.5A EP3356363A1 (fr) 2015-09-30 2016-09-30 Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles
SV2018005657A SV2018005657A (es) 2015-09-30 2018-03-22 "nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen"
PH12018500650A PH12018500650A1 (en) 2015-09-30 2018-03-23 New imidazo [4,5-b] pyridine derivatives, a process for their preparation and pharmaceutical compositions containing them
NI201800043A NI201800043A (es) 2015-09-30 2018-03-23 Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1
IL258341A IL258341A (en) 2015-09-30 2018-03-25 New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
CL2018000783A CL2018000783A1 (es) 2015-09-30 2018-03-26 Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECIEPI201823253A ECSP18023253A (es) 2015-09-30 2018-03-26 NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
DO2018000083A DOP2018000083A (es) 2015-09-30 2018-03-27 NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CONC2018/0003473A CO2018003473A2 (es) 2015-09-30 2018-03-28 Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1559252 2015-09-30
FR1559252A FR3041639B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

Publications (2)

Publication Number Publication Date
FR3041639A1 FR3041639A1 (fr) 2017-03-31
FR3041639B1 true FR3041639B1 (fr) 2019-01-25

Family

ID=54979755

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1559252A Expired - Fee Related FR3041639B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

Country Status (26)

Country Link
US (1) US20180273528A1 (fr)
EP (1) EP3356363A1 (fr)
JP (1) JP2018535931A (fr)
KR (1) KR20180054858A (fr)
CN (1) CN108137581A (fr)
AU (1) AU2016333505A1 (fr)
BR (1) BR112018006157A2 (fr)
CA (1) CA2999935A1 (fr)
CL (1) CL2018000783A1 (fr)
CO (1) CO2018003473A2 (fr)
CR (1) CR20180181A (fr)
CU (1) CU20180028A7 (fr)
DO (1) DOP2018000083A (fr)
EA (1) EA201890821A1 (fr)
EC (1) ECSP18023253A (fr)
FR (1) FR3041639B1 (fr)
HK (1) HK1255804A1 (fr)
IL (1) IL258341A (fr)
MA (1) MA43020A (fr)
MX (1) MX2018003860A (fr)
NI (1) NI201800043A (fr)
PE (1) PE20181331A1 (fr)
PH (1) PH12018500650A1 (fr)
SV (1) SV2018005657A (fr)
TN (1) TN2018000090A1 (fr)
WO (1) WO2017055530A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108822103A (zh) * 2018-07-28 2018-11-16 刘凤娟 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用
CA3118093A1 (fr) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibiteurs a petites molecules de dyrk1/clk et leurs utilisations
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
EP4028005A4 (fr) * 2019-09-11 2023-09-20 Prelude Therapeutics, Incorporated Inhibiteurs de cdk et leur utilisation en tant que produits pharmaceutiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970200A1 (fr) * 2013-03-13 2016-01-20 Abbvie Inc. Inhibiteurs de pyridine cdk9 kinase

Also Published As

Publication number Publication date
SV2018005657A (es) 2018-07-31
CL2018000783A1 (es) 2018-09-21
JP2018535931A (ja) 2018-12-06
MX2018003860A (es) 2018-08-16
PE20181331A1 (es) 2018-08-20
IL258341A (en) 2018-05-31
CO2018003473A2 (es) 2018-07-10
AU2016333505A1 (en) 2018-04-19
CA2999935A1 (fr) 2017-04-06
ECSP18023253A (es) 2018-04-30
HK1255804A1 (zh) 2019-08-23
WO2017055530A1 (fr) 2017-04-06
EP3356363A1 (fr) 2018-08-08
CR20180181A (es) 2018-06-22
CU20180028A7 (es) 2018-07-05
DOP2018000083A (es) 2018-10-15
US20180273528A1 (en) 2018-09-27
KR20180054858A (ko) 2018-05-24
NI201800043A (es) 2018-06-21
PH12018500650A1 (en) 2018-10-01
MA43020A (fr) 2018-08-08
BR112018006157A2 (pt) 2018-10-09
TN2018000090A1 (en) 2019-07-08
CN108137581A (zh) 2018-06-08
EA201890821A1 (ru) 2018-10-31
FR3041639A1 (fr) 2017-03-31

Similar Documents

Publication Publication Date Title
MA35903B1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA45222B1 (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
FR3037958B1 (fr) Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA37213B1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA45223B1 (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA42232B1 (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
EA201170769A1 (ru) Органические соединения
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA32942B1 (fr) Composes organiques
UA110347C2 (uk) ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
MA38099B1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
MA50391B1 (fr) Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
EA201691934A1 (ru) Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1
MA38091A2 (fr) Dérivés n-(pyridin-2-yl)pyrimidin-4-amines contenant un groupe sulfoximine

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20170331

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

ST Notification of lapse

Effective date: 20200906